The Italian Network for Pediatric Clinical Trials.
Mission and Vision
We are a contact and coordination center for all national and international pediatric clinical trials involving Italian clinical sites, which are clinical excellences in the pediatric field.
We are committed to promoting the growth and quality of pediatric clinical trials in Italy. We give concrete support to the planning, conduct and completion of all types of pediatric clinical trials (profit and non-profit).
Partners
Azienda Ospedaliero-Universitaria Bari
Azienda Ospedaliero-Universitaria BariConsorzio per Valutazioni Biologiche e Farmacologiche (CVBF)
IRCCS Istituto Ortopedico Rizzoli
A.I.E.O.P. Italian Association of Pediatric Hematology Oncology
IRCCS Academic Hospital of BolognaASST Spedali Civili
Azienda Ospedaliera Brotzu
S.C. Clinica di Neuropsichiatria dell'Infanzia e dell'adolescenzaIRCCS Azienda Ospedaliero Universitaria Meyer
Istituto Giannina Gaslini
Istituto Giannina GasliniIRCCS Ospedale San Raffaele Milano
SIF - The Italian Society of Pharmacology
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Università di Padova
Pedianet
Fondazione Penta ONLUS
A.I.E.O.P. Italian Association of Pediatric Hematology Oncology
IRCCS Academic Hospital of BolognaTEDDY European Network of Excellence for Paediatric Research
IRCCS Fondazione Stella Maris
Università di PisaOspedale Pediatrico Bambino Gesù
A.O.U. Regina Margherita
Città della Salute e della Scienza TorinoIRCCS Materno Infantile Burlo Garofolo Trieste
Activieties and Services
Thanks to the detailed knowledge of the clinical sites and the expertise Members and the Coordination Center of the Consortium, INCiPiT acts as a facilitator in the set up and conduct of pediatric clinical trials through Sponsorship, Coordination, Training and Networking activities and specific dedicated services.
New EU Regulation on
Clinical Trials
It has been applied since 31 January 2022 and aims to create a favorable environment for conducting clinical trials in Europe, guaranteeing consistency in the rules, increasing transparency, guaranteeing certain and stringent deadlines in the evaluation and approval of studies.
